None listed
Conditions
Brief summary
The primary aim of this trial is to evaluate if motivational interviews (MI) promote adherence to recommended life-style changes and secondary prevention strategies to reduce stroke re-occurrence as compared with usual care. We hypothesise that community-based secondary stroke prevention via MI will effectively improve adherence to medications and life-style changes recommended by treating physicians at and after hospital discharge during the first 12 months after the initial stroke.
Interventions
Motivational interviewing (MI) is a structured, patient-focused, and cost-effective intervention designed to motivate patients to adhere to medication and life-style change recommendations. The MI group will have 4 interviews with trained research nurses. The initial interview will be in-person with patient & family caregivers the day before hospital discharge. Remaining interviews will be done via telephone at 3, 6, and 9 months. Interviews will take up to 1 hr. The intervention will be standardised and sessions will be monitored via standard MI coding, with detailed instructions to guide sessions and ensure consistency across research nurses. Though this study examines the impact of MI on individuals’ post-stroke, recommendations for lifestyle/medication change often fail without support from significant others. Thus, caregivers will be invited to attend the initial session, but this will not be required. Caregiver attendance will be recorded.
Sponsors
Study design
Eligibility
Inclusion criteria
(1) First-ever stroke (excluding subarachnoid haemorrhage) (2) discharged from hospital (3) consented to participate in the trial
Exclusion criteria
Individuals will be excluded if they: (a) have significant impairments precluding participation (e.g., aphasia, psychiatric conditions or cognitive impairment [defined as Mini Mental State Examination (MMSE) <23]); (b) are unable to converse in English, which would impact assessment and intervention delivery; (c) cannot give informed consent; (e) are known to have another condition likely to impact their participation in the trial (e.g., life-threatening condition other than cardiovascular disease); (d) receiving psychiatric or clinical psychology treatment that can contaminate the study intervention; or (e) are likely to move out of the study area after discharge.